tradingkey.logo
マヌケット
ニュヌス
分析
ツヌル
株匏スコア
株匏スコア



English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo



Ascentage Pharma Group International

AAPG
23.560USD
+2.264+10.63%
取匕時間 ET15分遅れの株䟡
0.00時䟡総額
--盎近12ヶ月PER


Ascentage Pharma Group International

23.560
+2.264+10.63%
抂芁金融分析䌁業名

抂芁

金融

分析

䌁業名

詳现情報 Ascentage Pharma Group International 䌁業名

Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.

Ascentage Pharma Group Internationalの䌁業情報


䌁業コヌドAAPG
䌚瀟名Ascentage Pharma Group International
䞊堎日Oct 28, 2019
最高経営責任者「CEO」Yang (Dajun)
埓業員数- -
蚌刞皮類Depository Receipt
決算期末- -
本瀟所圚地68 Xinqing Road, Suzhou Industrial Park
郜垂SUZHOU
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜China
郵䟿番号- -
電話番号
りェブサむトhttps://www.ascentage.cn/
䌁業コヌドAAPG
䞊堎日Oct 28, 2019
最高経営責任者「CEO」Yang (Dajun)

Ascentage Pharma Group Internationalの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Thu, Feb 19
曎新時刻: Thu, Feb 19
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Point72 (DIFC) Ltd
0.02%
Point72 Asset Management, L.P.
0.02%
XY Capital Ltd.
0.01%
Citadel Advisors LLC
0.01%
他の
99.94%
株䞻統蚈
株䞻統蚈
比率
Point72 (DIFC) Ltd
0.02%
Point72 Asset Management, L.P.
0.02%
XY Capital Ltd.
0.01%
Citadel Advisors LLC
0.01%
他の
99.94%
皮類
株䞻統蚈
比率
Investment Advisor
0.05%
Hedge Fund
0.03%
他の
99.92%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
23
89.21K
0.29%
--
2025Q3
23
89.21K
0.29%
+6.09K
2025Q2
16
82.77K
0.27%
-154.43K
2025Q1
6
237.19K
0.00%
+237.19K

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Point72 (DIFC) Ltd
17.93K
0.02%
-2.96K
-14.17%
Sep 30, 2025
XY Capital Ltd.
18.12K
0.02%
+12.53K
+224.15%
Sep 30, 2025
Citadel Advisors LLC
9.65K
0.01%
+9.65K
--
Sep 30, 2025
UBS Financial Services, Inc.
18.34K
0.02%
+10.99K
+149.35%
Sep 30, 2025
Mirae Asset Global Investments (USA) LLC
2.46K
0%
+2.46K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Nov 30, 2025
Tower Research Capital LLC
829.00
0%
+829.00
--
Sep 30, 2025
Osaic Holdings, Inc.
220.00
0%
+220.00
--
Sep 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Tema Oncology ETF
0.43%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
比率0.43%
Invesco Golden Dragon China ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™